Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Tina Biss.

Newcastle AuthorsTitleYearFull text
Dr Emma Kampouraki
Dr Peter Avery
Dr Tina Biss
Dr Hilary Wynne
Professor Farhad Kamali
et al.
Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients2021
Dr Emma Kampouraki
Dr Salah Abohelaika
Dr Peter Avery
Dr Tina Biss
Dr Hilary Wynne
et al.
Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing2021
Dr Tina Biss
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT)2020
Dr Tina Biss
Severity and Features of Epistaxis in Children with a Mucocutaneous Bleeding Disorder2018
Dr Tina Biss
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura2017
Dr Tina Biss
Challenges in adolescent venous thromboembolism2016
Salah Abohelaika
Dr Tina Biss
Dr Hilary Wynne
Professor Farhad Kamali
C0170: The Impact of Dietary Vitamin K on the Pharmacological Activity of FXa Inhibitor Rivaroxaban in Man2014
Dr Tina Biss
Professor Farhad Kamali
Characterizing variability in warfarin dose requirements in children using modelling and simulation2014
Dr Tina Biss
Bruce Jaffray
Risk Stratification for the Use of Thromboprophylaxis in Young People With IBD Requires Further Evaluation2014
Salah Abohelaika
Dr Tina Biss
Dr Peter Murphy
Professor Farhad Kamali
The impact of dietary vitamin K on the pharmacological activity of FXa inhibitor rivaroxaban in man2014
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children2013
Dr Tina Biss
Dr Peter Avery
Julian Leathart
Professor Farhad Kamali
VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children2012
Dr Tina Biss
Professor Farhad Kamali
Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?2012
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
Warfarin dose prediction in children using pharmacogenetics information2012
Dr Tina Biss
Dr Peter Avery
Julian Leathart
Professor Farhad Kamali
Warfarin dose prediction in children using pharmacogenetics information2012
Dr Tina Biss
Dr Peter Avery
Julian Leathart
Dr John Hanley
Professor Ann Daly
et al.
VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children2011
Dr Tina Biss
-1 to+4 vs. 0 to+3?: comparing scoring systems for bleeding symptoms in the condensed mcmdm-1 VWD and the pediatric bleeding questionnaires2011
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children2011
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
Comparison of time within therapeutic INR range with percentage INR within therapeutic range for assessing long-term anticoagulation control in children [reply to a rebuttal]2011
Dr Tina Biss
Professor Ashley Adamson
Emeritus Professor Chris Seal
Professor Farhad Kamali
The potential impact of dietary vitamin K status on anticoagulation control in children receiving warfarin2011
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
Warfarin treatment outcomes in children monitored at home with a point-of-care device2011
Dr Tina Biss
Evaluation of the Severity and Pattern of Epistaxis In Children with a Mucocutaneous Bleeding Disorder and In Healthy Children Using a Standardized Questionnaire2010
Dr Tina Biss
Evaluation of Bleeding Symptoms in Children with An Inherited Mucocutaneous Bleeding Disorder2009
Dr Tina Biss
Dr Katherine Talks
Intracranial Haemorrhage in Patients with An Inherited Bleeding Disorder: A Review of 10 Years Experience in a UK Haemophilia Comprehensive Centre2009
Dr Tina Biss
Dr John Hanley
Use of recombinant factor VIIa (rFVIIa) in the management of intractable haemorrhage - A survey of current UK practice2007
Dr Tina Biss
Dr John Hanley
Clinical scoring systems to guide the use of recombinant activated factor VII (rFVIIa) in major haemorrhage2006
Dr Tina Biss
Dr Mark Velangi
Dr John Hanley
Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature2006
Dr Tina Biss
Dr John Hanley
Recombinant activated factor VII (rFVIIa/NovoSeven®) in intractable haemorrhage: Use of a clinical scoring system to predict outcome2006
Dr Tina Biss
Dr John Hanley
Andrew Loughney
Recombinant activated factor VII in the management of major obstetric haemorrhage2006
Dr Tina Biss
Dr John Hanley
The use of recombinant factor VIIa in the management of major haemorrhage: Experience within the northern region of the UK2005
Dr Tina Biss
Dr Peter Hamilton
Myelofibrosis and angiodysplasia of the colon: another manifestation of portal hypertension and massive splenomegaly?2004
Dr Tina Biss
Dr Lucy Crossman
Dr John Hanley
An acquired factor VIII inhibitor in association with a myeloproliferative/myelodysplastic disorder presenting with severe subcutaneous haemorrhage2003